Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy

Results from a clinical trial demonstrate that a 14-gene molecular assay can identify patients with early-stage nonsquamous non–small cell lung cancer who could benefit from adjuvant chemotherapy after surgery. Patients who received adjuvant chemotherapy had a significantly lower risk of cancer recurrence compared to the observation group. The trial's interim results show promise for more precise, biomarker-driven therapy decisions.